Zogenix Announces Departure of Chief Commercial Officer, Scott Shively

Zogenix Announces Departure of Chief Commercial Officer, Scott Shively

SAN DIEGO, Aug. 1, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a
pharmaceutical company developing and commercializing products for the
treatment of pain-related conditions and central nervous system disorders,
today announced that Scott Shively has resigned as Chief Commercial Officer in
order to pursue another opportunity. In the interim, Roger Hawley, the
Company's Chief Executive Officer, will assume the duties and responsibilities
of the Chief Commercial Officer and lead the continued launch and commercial
activities.

"Scott has laid a solid foundation for our expanded commercial team and we
wish him success in his new endeavor," commented Roger Hawley, Chief Executive
Officer. "Our experienced commercial team is already fully engaged in carrying
out all planned activities and we expect continued growth without disruption.
I look forward to leading the sales, marketing, managed care and trade teams
to further direct focus to the commercial success of the Company."

Mr. Hawley, one of the co-founders of Zogenix, has extensive experience in
leading commercial organizations with his prior experience at multiple
pharmaceutical companies.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to
developing and commercializing therapies that address specific clinical needs
for people living with pain-related conditions and CNS disorders who need
innovative treatment alternatives to help them return to normal daily
functioning.

Forward-Looking Statements

Zogenix cautions you that statements included in this press release that are
not a description of historical facts are forward-looking statements. Words
such as "believes," "anticipates," "plans," "expects," "indicates," "will,"
"intends," "potential," "suggests," "assuming," "designed" and similar
expressions are intended to identify forward-looking statements. These
statements are based on the company's current beliefs and expectations. These
forward-looking statements include statements regarding: the continued efforts
related to the commercialization of Zogenix products and the ability to carry
out planned activities without disruption. Actual results may differ from
those set forth in this press release due to the risk and uncertainties
inherent in Zogenix's business, including, without limitation: Zogenix's
dependence on its remaining key personnel; Zogenix may be unable to achieve
broad market acceptance and generate significant revenues from sales of its
products; and other risks detailed in Zogenix's prior press releases as well
as in public periodic filings with the Securities and Exchange Commission. You
are cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof, and Zogenix undertakes no obligation
to revise or update this press release to reflect events or circumstances
after the date hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement. This caution is made under the safe
harbor provisions of Section 21E of the Private Securities Litigation Reform
Act of 1995.

CONTACT: Investors
         Zack Kubow |The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com
 
Press spacebar to pause and continue. Press esc to stop.